Developing contrast-induced nephropathy (CIN) after primary percutaneous coronary intervention (pPCI) has a negative impact on survival and morbidity. We assessed the predictive value of serum uric acid (SUA) for the development of CIN in patients with ST-segment elevation myocardial infarction (STEMI) who underwent pPCI. Contrast-induced nephropathy was defined an increase of ≥25% or ≥0.5 mg/dL in creatinine concentrations within 72 hours after pPCI. Patients were divided into 2 groups according to admission median SUA level. Serum uric acid level was <5.4 mg/dL (group 1; n = 222) and ≥5.4 mg/dL (group 2; n = 228). Compared to group 1, development of CIN (12% vs 20%, P < .001) was significantly greater in group 2. Using a cut point of >5.45 mg/dL, the SUA level predicted development of CIN with a sensitivity of 70% and specificity of 67%. In multiple logistic regression analysis, SUA level, diabetes mellitus, left ventricular ejection fraction <50%, contrast volume, estimated glomerular filtration rate, and C-reactive protein level emerged as independent predictors of CIN. In conclusion, elevated SUA is an independent risk factor for the development of CIN after pPCI in patients with STEMI.
McCulloughPA. Contrast-induced acute kidney injury. J Am Coll Cardiol. 2008;51(15):1419–1428.
2.
KanbayMCovicACocaSGTurgutFAkcayAParikhCR. Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. Int Urol Nephrol. 2009;41(3):617–627.
3.
KatsikiNAthyrosVGKaragiannisAMikhailidisDP. Contrast-Induced Nephropathy: An “All or None” Phenomenon?Angiology. 2015;66(6):508–513.
4.
MehranRAymongEDNikolskyE. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol. 2004;44(7):1393–1399.
5.
GoldenbergIMatetzkyS. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172(11):1461–1471.
6.
KanbayMSolakYDoganELanaspaMACovicA. Uric acid in hypertension and renal disease: the chicken or the egg?Blood Purif. 2010;30(4):288–295.
7.
KanbayMSegalMAfsarBKangDHRodriguez-IturbeBJohnsonRJ. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart. 2013;99(11):759–766.
8.
KanbayMIkizekMSolakY. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol. 2011;33(4):325–331.
9.
KanbayAInonuHSolakY. Uric acid as a potential mediator of cardiovascular morbidity in obstructive sleep apnea syndrome. Eur J Intern Med. 2014;25(5):471–476.
10.
TurakOAfsarBOzcanF. Relationship between elevated morning blood pressure surge, uric acid, and cardiovascular outcomes in hypertensive patients. J Clin Hypertens (Greenwich). 2014;16(7):530–535.
11.
KanbayMJensenTSolakY. Uric acid in metabolic syndrome: from an innocent bystander to a central player [published online December 15, 2015]. Eur J Intern Med. 2015.
12.
TakirMKostekOOzkokA. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. J Investig Med. 2015;63(8):924–929.
13.
ToprakOCiritMEsiEPostaciNYesilMBayataS. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv. 2006;67(2):227–235.
14.
BarbieriLVerdoiaMSchafferA; Novara Atherosclerosis Study Group (NAS). Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI. Nutr Metab Cardiovasc Dis. 2015;25(2):181–186.
15.
LiuYTanNChenJ. The relationship between hyperuricemia and the risk of contrast-induced acute kidney injury after percutaneous coronary intervention in patients with relatively normal serum creatinine. Clinics (Sao Paulo). 2013;68(1):19–25.
16.
ToprakOCiritMYesilM. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant. 2007;22(3):819–826.
17.
ElbasanZSahinDYGurM. Contrast-induced nephropathy in patients with ST elevation myocardial infarction treated with primary percutaneous coronary intervention. Angiology. 2014;65(1):37–42.
18.
KarabulutASahinIIlker AvciI. Impact of serum alkaline phosphatase level on the pathophysiologic mechanism of contrast-induced nephropathy. Kardiol Pol. 2014;72(10):977–982.
19.
KowalczykJFrancuzPSwobodaR. Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. Nephron Clin Pract. 2010;116(2):c114–c122.
20.
SaritemurMTurkeliMKalkanKTanbogaIHAksakalE. Relation of uric acid and contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention in the ED. Am J Emerg Med. 2014;32(2):119–123.
21.
ParkSHShinWYLeeEY. The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circ J. 2011;75(3):692–697.
22.
GuoWLiuYChenJY. Hyperuricemia Is an Independent Predictor of Contrast-Induced Acute Kidney Injury and Mortality in Patients Undergoing Percutaneous Coronary Intervention. Angiology. 2015;66(8):721–726.
23.
MorcosSKThomsenHSWebbJA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–1613.
24.
NicolaRShaqdanKWAranKMansouriMSinghAAbujudehHH. Contrast-Induced Nephropathy: Identifying the Risks, Choosing the Right Agent, and Reviewing Effective Prevention and Management Methods. Curr Probl Diagn Radiol. 2015;44(6):501–504.
25.
BhattHTurkistaniASanghaniDJulliardKFernaineG. Do Cardiovascular Risk Factors and Coronary SYNTAX Score Predict Contrast Volume Use During Cardiac Catheterization?Angiology. 2015;66(10):933–940.
26.
ErolTTekinAKatircibasiMT. Efficacy of allopurinol pretreatment for prevention of contrast-induced nephropathy: a randomized controlled trial. Int J Cardiol. 2013;167(4):1396–1399.
27.
KumarABhawaniGKumariNMurthyKSLalwaniVRaju ChN. Comparative study of renal protective effects of allopurinol and N-acetyl-cysteine on contrast induced nephropathy in patients undergoing cardiac catheterization. J Clin Diagn Res. 2014;8(12):hc03–hc07.
28.
KelleyWN. Uricosuria and x-ray contrast agents. N Engl J Med. 1971;284(17):975–976.
29.
PostlethwaiteAEKelleyWN. Uricosuric effect of radiocontrast agents. A study in man of four commonly used preparations. Ann Intern Med. 1971;74(6):845–852.
30.
SchepersMSvan BallegooijenESBangmaCHVerkoelenCF. Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int. 2005;68(4):1543–1553.
31.
EjazAAAlquadanKFDassBShimadaMKanbayMJohnsonRJ. Effects of Serum Uric Acid on Estimated GFR in Cardiac Surgery Patients: A Pilot Study. Am J Nephrol. 2015;42(6):402–409.
32.
RyuESKimMJShinHS. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol. 2013;304(5):f471–f480.
33.
KanbayMHuddamBAzakA. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–1894.
34.
KanbayMSiriopolDNistorI. Effects of allopurinol on endothelial dysfunction: a meta-analysis. Am J Nephrol. 2014;39(4):348–356.
35.
AykasFSolakYErdenA. Persistence of cardiovascular risk factors in women with previous preeclampsia: a long-term follow-up study. J Investig Med. 2015;63(4):641–645.
36.
KanbayMYilmazMISonmezA. Serum uric acid independently predicts cardiovascular events in advanced nephropathy. Am J Nephrol. 2012;36(4):324–331.
37.
KangDHParkSKLeeIKJohnsonRJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16(12):3553–3562.
